Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (10), 764-775

Assessment of Anti-Diabetic Activity of Peanut Shell Polyphenol Extracts

Affiliations

Assessment of Anti-Diabetic Activity of Peanut Shell Polyphenol Extracts

Xiao-Meng Sun et al. J Zhejiang Univ Sci B.

Abstract

The present study aimed to evaluate the anti-diabetic property of peanut shell polyphenol extracts (PSPEs). Diabetic rats were oral-administrated with PSPE at doses of 50, 100, and 200 mg/kg body weight (BW) per day for 28 consecutive days, with metformin (Met) as a positive control. The results showed that, similar to the Met treatment, administration of PSPE caused significant decreases in food intake, water intake, fasting blood glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and methane dicarboxylic aldehyde in serum, and significant increases in BW, insulin level, high-density lipoprotein cholesterol, superoxide dismutase, glutathione, and liver glycogen. Further, glucose tolerance was markedly improved in the PSPE-treated diabetic groups. Histopathological results showed that PSPE improved cellular structural and pathological changes in liver, kidney, and pancreatic islets. Collectively, the results indicated that the hypoglycemic effects of PSPE on high-fat diet/streptozotocin (HFD/STZ)-induced diabetes are comparable to Met, though their exact mechanism actions are still under investigation. Therefore, the current study suggests that PSPE could be a potential health-care food supplement in the management of diabetes.

Keywords: Peanut shell polyphenol extract (PSPE); Anti-diabetic activity; Streptozotocin (STZ).

Conflict of interest statement

Compliance with ethics guidelines: Xiao-meng SUN, Hai-qing YE, Jing-bo LIU, Lei WU, Ding-bo LIN, Ya-li YU, and Feng GAO declare that they have no conflict of interest.

All institutional and national guidelines for the care and use of laboratory animals were followed.

Figures

Fig. 1
Fig. 1
Profiles of peanut shell polyphenol extracts (a) Peanut shell polyphenols by HPLC. 1, pyrogallol; 2, catechol; 3, phloroglucinol; 4, quercetin; 5, luteolin. (b) Molecular structures of luteolin, pyrogallol, catechol, phloroglucinol, and quercetin
Fig. 2
Fig. 2
Effect of PSPE on fasting blood glucose level in diabetic rats Results are expressed as the mean±SD (n=7). NCG: normal control group; DCG: diabetic control group; MG: diabetic rats treated with Met (200 mg/kg); PSPE 50: diabetic rats treated with PSPE (50 mg/kg, oral); PSPE 100: diabetic rats treated with PSPE (100 mg/kg, oral); PSPE 200: diabetic rats treated with PSPE (200 mg/kg, oral). ## P<0.01, compared with NCG; * P<0.05, ** P<0.01, compared with DCG
Fig. 3
Fig. 3
Effect of PSPE on oral glucose tolerance test Results are expressed as the mean±SD (n=7). NCG: normal control group; DCG: diabetic control group; MG: diabetic rats treated with Met (200 mg/kg); PSPE 50: diabetic rats treated with PSPE (50 mg/kg, oral); PSPE 100: diabetic rats treated with PSPE (100 mg/kg, oral); PSPE 200: diabetic rats treated with PSPE (200 mg/kg, oral). ## P<0.01, compared with NCG; ** P<0.01, compared with DCG
Fig. 4
Fig. 4
Effects of PSPE on morphological changes of liver in diabetic rats (a) Normal control group; (b) Diabetic control group; (c) Diabetic rats treated with Met (200 mg/kg); (d) Diabetic rats treated with PSPE (50 mg/kg); (e) Diabetic rats treated with PSPE (100 mg/kg); (f) Diabetic rats treated with PSPE (200 mg/kg). Arrows: 1, swelling; 2, inflammatory cell infiltration
Fig. 5
Fig. 5
Effects of PSPE on morphological changes of kidneys in diabetic rats (a) Normal control group; (b) Diabetic control group; (c) Diabetic rats treated with Met (200 mg/kg); (d) Diabetic rats treated with PSPE (50 mg/kg); (e) Diabetic rats treated with PSPE (100 mg/kg); (f) Diabetic rats treated with PSPE (200 mg/kg). Arrows: glomeruli with mesangiocapillary proliferation
Fig. 6
Fig. 6
Effects of PSPE on morphological changes of pancreas in diabetic rats (a) Normal control group; (b) Diabetic control group; (c) Diabetic rats treated with Met (200 mg/kg); (d) Diabetic rats treated with PSPE (50 mg/kg); (e) Diabetic rats treated with PSPE (100 mg/kg); (f) Diabetic rats treated with PSPE (200 mg/kg)

Similar articles

See all similar articles
Feedback